


3,6-Dihydroxyxanthone

Cat. No.:	HY-W031510
CAS No.:	1214-24-0
Molecular Formula:	C ₁₃ H ₈ O ₄
Molecular Weight:	228.2
Target:	Others
Pathway:	Others
Storage:	4°C, stored under nitrogen
	* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)



SOLVENT & SOLUBILITY

In Vitro

DMSO : 50 mg/mL (219.11 mM; Need ultrasonic)

	Solvent Concentration	Mass	1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM		4.3821 mL	21.9106 mL	43.8212 mL
	5 mM		0.8764 mL	4.3821 mL	8.7642 mL
	10 mM		0.4382 mL	2.1911 mL	4.3821 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

3,6-Dihydroxyxanthone (compound 3) is a xanthone derivatives. 3,6-Dihydroxyxanthone (compound 3) has anticancer activity. 3,6-Dihydroxyxanthone (compound 3) can be used for cancer research^[1].

In Vitro

3,6-Dihydroxyxanthone (compound 3) (3.906-1000 µg/mL; 24 hours) exhibits cytotoxic activity against WiDR and Vero cell lines with IC₅₀ values of 785.58 and 1280.9 µM^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cytotoxicity Assay^[1]

Cell Line:	WiDR and Vero cell lines
Concentration:	3.906, 7.813, 15.625, 31.25, 62.5, 125, 250 and 500 µg/mL (WiDR cell line) 7.813, 15.625, 31.25, 62.5, 125, 250, 500 and 1000 µg/mL (Vero cell line)
Incubation Time:	24 hours
Result:	Inhibited cell activity and with IC ₅₀ values of 785.58 and 1,280.9 µM for WiDR and Vero cell lines.

REFERENCES

[1]. Miladiyah I, et, al. Biological activity, quantitative structure-activity relationship analysis, and molecular docking of xanthone derivatives as anticancer drugs. Drug Des Devel Ther. 2018 Jan 15;12:149-158.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA